Last reviewed 2026-04-19 · How we verify

Juvenile Idiopathic Arthritis with Extended Oligoarticular Course

37 treatments

Approved treatments

tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer
tumor necrosis factor inhibitors (TNFi) · Pfizer

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

Juvenile Idiopathic Arthritis with Extended Oligoarticular Course patent landscape — cliff calendar, originator estates, attackable patents
Juvenile Idiopathic Arthritis with Extended Oligoarticular Course treatment landscape brief
Juvenile Idiopathic Arthritis with Extended Oligoarticular Course treatment updates RSS

Frequently asked questions about Juvenile Idiopathic Arthritis with Extended Oligoarticular Course

What drugs treat Juvenile Idiopathic Arthritis with Extended Oligoarticular Course?

Tracked treatments include tumor necrosis factor inhibitors (TNFi).

What is the treatment for Juvenile Idiopathic Arthritis with Extended Oligoarticular Course?

Standard treatment for Juvenile Idiopathic Arthritis with Extended Oligoarticular Course includes tumor necrosis factor inhibitors (TNFi). See the treatment landscape page for first-line, second-line and salvage options.

Treatment landscape: Juvenile Idiopathic Arthritis with Extended Oligoarticular Course patent cliff · Juvenile Idiopathic Arthritis with Extended Oligoarticular Course CI report
Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing